Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | CBFB | Q13951 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335253 | 1.00 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16656143 | 0.89 | CCR1 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL25195228 | 0.85 | LMNA (0.54) | NPC1RAB9ACCR1CCR5CCR8 | |
| SCHEMBL29419008 | 0.85 | LMNA (0.54) | NPC1RAB9ACCR1CCR5CCR8 | |
| SCHEMBL2467429 | 0.84 | CLK4 (0.59) | RXFP1NPC1RAB9ACCR1CCR5 | |
| SCHEMBL2614947 | 0.84 | PDE10A (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL20086110 | 0.84 | HAO1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13341651 | 0.83 | NPC1 (0.62) | RXFP1NPC1RAB9ACASP3SENP7 | |
| SCHEMBL20086109 | 0.82 | CYP19A1 (0.45) | RXFP1NPC1RAB9ACASP3SENP7 | |
| SCHEMBL15258007 | 0.82 | ALDH1A1 (0.57) | RXFP1NPC1RAB9ATNKSMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727953-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | claimed |
| WO-2024256358-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-19 | — | — | WO | claimed |
| US-20230167144-A1 | PREPARATION AND ITS APPLICATION OF A CYANIDE-BRIDGED METAL ORGANIC COMPOUND WITH INTRAMOLECULAR MAGNETIC TRANSFORMATION | Hubei Jingmen Industrial Technology Research Institute Co., Ltd. (CN) | 2023-06-01 | — | — | US | claimed |
| CN-115094463-A | Sub-nanometer alloy material and preparation method and application thereof | 中国科学院上海高等研究院 | 2022-09-23 | — | — | CN | claimed |
| CN-110628038-A | Covalent triazine organic framework, limited-area metal catalyst, preparation method and application | 中国科学院上海高等研究院 | 2019-12-31 | — | — | CN | claimed |
| EP-4735170-A1 | METATHESIS COMPOSITIONS COMPRISING AIR-STABLE IMIDO ALKYLIDENE COMPLEXES | Verbio SE (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4727953-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. Hoffmann-La Roche AG (CH) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025003441-A1 | METATHESIS COMPOSITIONS COMPRISING AIR-STABLE IMIDO ALKYLIDENE COMPLEXES | VERBIO VEREINIGTE BIOENERGIE AG (DE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024256358-A2 | ACCELERATED MARKING OF 5-FORMYL CYTOSINE AND USE IN NUCLEIC ACID METHYLATION SEQUENCING | F. HOFFMANN-LA ROCHE AG (CH) | 2024-12-19 | — | — | WO | disclosed |
| US-11890604-B2 | Composite catalyst for carbon dioxide reduction and method of fabricating of the same | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-02-06 | — | — | US | disclosed |
| US-11773074-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773074-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-10-03 | — | — | US | disclosed |
| US-8455690-B2 | Method for producing arylhydroxylamine | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-7872059-B2 | Polyurethanes, acryl resins, and metal (cobalt, nickel, palladium, and/or ruthenium); engravable flexographic printing plate precursor | FUJIFILM CORPORATION (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20100113830-A1 | METHOD FOR PRODUCING ARYLHYDROXYLAMINE | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2154125-A1 | METHOD FOR PRODUCING ARYLHYDROXYLAMINE | Wako Pure Chemical Industries, Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080194762-A1 | Polyurethanes, acryl resins, and metal (cobalt, nickel, palladium, and/or ruthenium); engravable flexographic printing plate precursor | FUJIFILM CORPORATION (JP) | 2008-08-14 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113830-A1 | METHOD FOR PRODUCING ARYLHYDROXYLAMINE | PAH, APEH, HPD | CA12 653/4885CA1 129/4885CA2 442/4885 |
| US-11773074-B2 | Method for aerobic oxidative coupling of thiophenes with a ligand-supported palladium catalyst | PPOX, TST, COX6C | CA12 3670/4885CA1 3405/4885CA2 2851/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | CA12 3362/4885CA1 3401/4885CA2 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.